[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Pages 2579-2580]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01507]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Johnson 
Matthey Pharmaceutical Materials, Inc.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before April 8, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701

[[Page 2580]]

Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
November 8, 2018, Johnson Matthey Pharmaceutical Materials, Inc., 25 
Patton Road, Devens, Massachusetts 01434 applied to be registered as a 
bulk manufacturer of the following basic classes of controlled 
substances:

------------------------------------------------------------------------
         Controlled substances          Drug code         Schedule
------------------------------------------------------------------------
Amphetamine...........................       1100  II
Methylphenidate.......................       1724  II
Nabilone..............................       7379  II
Hydrocodone...........................       9193  II
Levorphanol...........................       9220  II
Alfentanil............................       9737  II
Remifentanil..........................       9739  II
Sufentanil............................       9740  II
------------------------------------------------------------------------

    The company plans to support its other manufacturing facilities 
located in West Deptford, New Jersey and Conshohocken, Pennsylvania 
with manufacturing and analytical testing.

    Dated: December 21, 2018.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-01507 Filed 2-6-19; 8:45 am]
 BILLING CODE 4410-09-P